Gecko has a hot piece of MedTech in its hands: a surgical glue that can stop bleeding from sutured tissues, and in the future could replace stitching altogether.
This technology was initially developed at MIT by a wonder team, but it was in France that it became a commercial project. Paris-based Gecko has the exclusive license for this bio-glue, and was founded by the original Boston team.
Shortly after, it went through its first fundraising and got €8M from French investors specializing in SMEs and healthcare (Omnes Capital, CM-CIC and CapDecisif Management).
Gecko has now raised an additional €22.5M in a series A2 round (A2 being the modest European twin of US series B rounds, perhaps?). There are two new big investors – Bpifrance (a very active investment arm of the French State) and Sofinnova, which is one of our top European Biotech VCs.
